Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Baijin Life Science Holdings's Debt-to-EBITDA or its related term are showing as below:
MNNGF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.1 Med: -0.78 Max: 15.96
Current: -0.87
During the past 13 years, the highest Debt-to-EBITDA Ratio of Baijin Life Science Holdings was 15.96. The lowest was -8.10. And the median was -0.78.
MNNGF's Debt-to-EBITDA is ranked worse than 100% of 905
companies
in the Retail - Cyclical industry
Industry Median: 2.39
vs MNNGF: -0.87
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Baijin Life Science Holdings Debt-to-EBITDA Related Terms
Baijin Life Science Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Luxury Goods subindustry, Baijin Life Science Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baijin Life Science Holdings Debt-to-EBITDA vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Baijin Life Science Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Baijin Life Science Holdings (MNNGF) has a Debt-to-EBITDA of -0.36 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Baijin Life Science Holdings. According to the industry distribution chart, Baijin Life Science Holdings ranks #999999 out of 905 companies in the Retail - Cyclical industry.
Is Baijin Life Science Holdings' Debt-to-EBITDA too high?
Baijin Life Science Holdings' current Debt-to-EBITDA is -0.36. Based on the distribution chart, Baijin Life Science Holdings ranks #999999 out of 905 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Baijin Life Science Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' Debt-to-EBITDA compare to TPR?
According to the Retail - Cyclical industry distribution chart, Baijin Life Science Holdings ranks #999999 out of 905 companies for Debt-to-EBITDA. This places Baijin Life Science Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 2.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Retail - Cyclical company?
The median Debt-to-EBITDA among Retail - Cyclical companies is 2.39, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Baijin Life Science Holdings. For the Retail - Cyclical industry, the median Debt-to-EBITDA is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baijin Life Science Holdings's current Debt-to-EBITDA is -0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Baijin Life Science Holdings (MNNGF) has a current Debt-to-EBITDA of -0.36. The stock's GF Value™ is $0.04, compared to a current price of $0.08 — trading 100% above its estimated fair value. The current Debt-to-EBITDA is -0.36. Baijin Life Science Holdings' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current Debt-to-EBITDA is -0.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?
Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued.
The current stock price of $0.08 is trading 100% above its estimated GF Value™ of $0.04.
Key valuation signals for MNNGF:
Debt-to-EBITDA: -0.36
GF Value™: $0.04 vs. price of $0.08 (100% above fair value)
No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
33GF Score
Get the complete analysis for MNNGF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNGF has been successfully added to your 
